May 28, 2025, 23:46

NIH: Mechanisms of Alcohol-Associated Cancers

This grant supports mechanistic research on how alcohol consumption contributes to cancer initiation, progression, and outcomes. It encourages studies that elucidate biological pathways linking alcohol use to carcinogenesis in both normal and transformed cells. Projects may focus on immunological, metabolic, genetic, or epigenetic mechanisms across various cancer types, with an emphasis on alcohol’s dose, pattern, and exposure duration. Clinical trials are not allowed.

Eligibility Criteria:

U.S. and foreign institutions of higher education
Nonprofits (with or without 501(c)(3) status)
For-profit organizations (including small businesses)
Government agencies (federal, state, county, tribal, local)
Public housing authorities
Independent school districts
Faith-based and community-based organizations
U.S. Territories, TCCUs, HBCUs, AANAPISIs, HSIs, and regional organizations
Multiple applications allowed if distinct in scope
No cost sharing required

Funding Details:

Funding Instrument: Grant
Activity Code: R01 Research Project Grant
Budget: Not capped; should reflect actual needs of project
Project Duration: Up to 5 years
Clinical Trials: Not allowed

Deadline:

Original Closing Date: May 7, 2026
Applications due by 5:00 PM local time
Expiration Date: May 8, 2026

Where to Go for Further Information:

FOA Number: PAR-25-093
Full FOA: PAR-25-093 on NIH
General Contact: NIH Grants Information – [email protected]
Scientific Contacts: See Section VII of FOA
Apply via Grants.gov or NIH ASSIST

Alcohol and Cancer alcohol mechanisms cancer cancer biology Cancer Metabolism carcinogenesis epigenetics immunology NCI NIAAA NIH OncoDaily Oncology public health research R01 grant

FDA has Granted Full Market Approval for Papzimeos - NIH

Kirsty Duncan։ Thirty-two Months Into Fighting Cancer...

World’s Nicest Judge Frank Caprio Dies at 88 After Brave Battle with Pancreatic Cancer

Weight Loss Trial Reports Success for Breast Cancer Patients at One Year Mark

IMvigor011 Trial Reports ctDNA as Predictor of Response to Adjuvant Atezolizumab in Bladder Cancer